Evogene
EVGN
15 hedge funds and large institutions have $52M invested in Evogene in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
14% more capital inflows, than outflows
Capital inflows: $4.47M | Capital outflows: $3.91M
2.51% more ownership
Funds ownership: 19.8% → 22.31% (+2.5%)
0% more funds holding
Funds holding: 15 → 15 (0)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.81M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.04M |
| 3 |
Moon Capital Management
New York
|
+$376K |
| 4 |
Senvest Management
New York
|
+$165K |
| 5 |
Waddell & Reed Financial
Overland Park,
Kansas
|
+$81.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
-$1.32M |
| 2 |
JP Morgan Chase
New York
|
-$945K |
| 3 |
Harvey Partners
Tarrytown,
New York
|
-$790K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$491K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$363K |
EVGN Hedge Fund Activity: Q4 2014 in Review
15 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2014, worth a combined $52M — down 20% from $65.1M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EVGN and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Goldman Sachs, adding an estimated $2.81M. The largest seller was Credit Suisse, exiting entirely with an estimated $1.32M sold.
- 15 institutional investors held Evogene (EVGN) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $52M of Evogene stock for Q4 2014, down 20% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q4 2014 and 2 closed out, a net change of -1 holder.
- The largest Evogene buyer in Q4 2014 was Goldman Sachs, an estimated $2.81M added.
- The largest Evogene seller in Q4 2014 was Credit Suisse, an estimated $1.32M sold.
Based on aggregated 13F filings for Q4 2014.